For your patients with HBV, HEPATITIS DELTA adds layers of risk for disease progression1

Act Now

BECAUSE OF THE SEVERITY OF HDV, SCREENING IS URGENTLY NEEDED

Recent guidance advises HDV screening for all HBsAg-positive patients2_4

Studies show that the prevalence of HDV in the US varies significantly due to inconsistent screening5

In recent studies, prevalence estimates for HDV in the US range from 1% to 5% of patients with HBV5

Results from a 2023 retrospective analysis of 1444 patients with chronic hepatitis B in the US indicated that 18% of patients with HDV would be missed under US-recommended risk-based screening approaches6

The study analyzed medical records for 11,190 patients diagnosed with chronic hepatitis B infection in a tertiary health system in a multicultural urban area in the US from January 2016 to December 2021. A total of 1444 of the patients with chronic hepatitis B were screened for HDV and 88 (6%) were positive for HDV antibodies.6

Persons from endemic regions are at the most significant risk for hepatitis delta3

In 2022, it was estimated that ~65,000 foreign-born individuals in the US were living with HDV infection7

Endemic regions8:

  • Africa (West Africa, Horn of Africa)
  • Asia (Central and Northern Asia, Vietnam, Mongolia, Pakistan, Japan, Taiwan)
  • Pacific Islands (Kiribati, Nauru)
  • Middle East (all countries)
  • Eastern Europe (Eastern Mediterranean regions, Turkey)
  • South America (Amazonian basin)
  • Other (Greenland)

HDV only infects people with HBV9

globe

HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HDV, hepatitis D virus.

Chronic hepatitis delta infection is the most severe and rapidly progressive form of chronic viral hepatitis9

HDV infection leads to a faster progression towards liver-related death and hepatocellular carcinoma (HCC)9

Patients infected with HBV/HDV can have more severe disease compared to individuals with HBV monoinfection1,10

2-3× more likely to develop cirrhosis

2-3× higher risk of death or liver transplantation

3-6× higher risk for hepatocellular carcinoma

HCC, hepatocellular carcinoma.

Screening recommendations

Recent guidance advises HDV screening for all HBsAg-positive patients2_4

All HBsAg-positive individuals should be screened for HDV at least once.4

– 2025 HBV Guidelines from the European Association for the Study of the Liver

  • The American Association for the Study of Liver Diseases (AASLD) recommends testing of HBsAg-positive persons at risk for HDV, which include8:
  • Immigrants from endemic regions:
    • Africa (West Africa, Horn of Africa)
    • Asia (Central and Northern Asia, Vietnam, Mongolia, Pakistan, Japan, Taiwan)
    • Pacific Islands (Kiribati, Nauru)
    • Middle East (all countries)
    • Eastern Europe (Eastern Mediterranean regions, Turkey)
    • South America (Amazonian basin)
    • Other (Greenland)
  • Low HBV DNA with unexplained ALT elevations should be considered

Map of Endemic Areas11

ALT, alanine aminotransferase; HCV, hepatitis C virus; HIV, human immunodeficiency virus; STD, sexually transmitted disease.

Challenges in the management of HDV
     
  • Antiviral treatment with nucleos(t)ide analogs is NOT effective against the hepatitis delta virus8
  • The goal of HDV treatment is reduction in HDV RNA levels, which typically leads to a normalization of ALT levels8
    • Suppression of HDV replication is associated with normalization of ALT and reduced necroinflammatory activity in the liver8

Resources

More information on hepatitis D
Centers for Disease Control and Prevention (CDC)
Hepatitis D information
Visit CDC.gov
World Health Organization (WHO)
Hepatitis D fact sheet
Visit WHO.int

References

References:

1. Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxf). 2019;7(4):231-245. doi:10.1093/ gastro/goz023 2. Ahn J, Gish RG. Hepatitis D virus: a call to screening. Gastroenterol Hepatol (NY). 2014;10(10):647-686. 3. Terrault NA, Ghany MG. Enhanced screening for hepatitis D in the USA: overcoming the delta blues. Dig Dis Sci. 2021;66:2483-2485. doi:10.1007/s10620-020-06584-w 4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502-583. doi:10.1016/ j.jhep.2025.03.018 5. Gish RG, Cohen C, Holden LR, et al. A call to reclassify the delta hepatitis virus as an orphan disease. Hepatol Commun. 2025;9:e0746. doi:10.1097/HC9.0000000000000746 6. Nathani R, Leibowitz R, Giri D, et al. The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection. J Viral Hepat. 2023;30:195-200. doi:10.1111/jvh.13779 7. Wong RJ, Brosgart C, Wong SS, et al. Estimating the prevalence of hepatitis delta virus infection among adults in the United States: A meta-analysis. Liver Int. 2024;44(7):1715-1734. doi:10.1111/liv.15921 8. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800 9. World Health Organization. Hepatitis D fact sheet. Updated July 25, 2025. Accessed September 18, 2025. https://www.who.int/news-room/fact-sheets/detail/hepatitis-d 10. Brancaccio G, Fasano M, Grossi A, Santantonio TA, Gaeta GB. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther. 2019;49(8):1071-1076. doi:10.1111/apt.15188 11. Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677-1687. doi:10.1093/ infdis/jiz633